| Unbound MEDLINE results for: | Bookmark this site | | Articles related to 18815561 [Unique ID], provided by the PubMed system | |
| |
|
| | 1 - 10 of 102 journal articles in the PubMed database | Email to a friend | | |
| Woltering EA, O'Dorisio TM, Vinik A, et al.
Comments on "Clinical Value of Monitoring Plasma Octreotide Levels During Chronic Octreotide Long-Acting Repeatable Therapy in Carcinoid Patients" [JOURNAL ARTICLE]
Pancreas 2008 Oct; 37(3):336-337.
Full Citation | Find Related Articles | | Schran HF, Hager DF
Comments on "Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients". [Comment, Letter]
Pancreas 2008 Oct; 37(3):334-5; author reply 336-7.
Full Citation | Find Related Articles | | Woltering EA, Salvo VA, O'Dorisio TM, et al.
Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients. [Journal Article]
Pancreas 2008 Jul; 37(1):94-100.
Abstract | Full Citation | Find Related Articles | | Woltering EA, Hilton RS, Zolfoghary CM, et al.
Validation of Serum Versus Plasma Measurements of Chromogranin A Levels in Patients With Carcinoid Tumors: Lack of Correlation Between Absolute Chromogranin A Levels and Symptom Frequency. [JOURNAL ARTICLE]
Pancreas 2006 Oct; 33(3):250-254.
Abstract | Full Citation | | Biermasz NR, Pereira AM, Smit JW, et al.
Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly. [Clinical Trial, Journal Article]
Growth Horm IGF Res 2005 Jun; 15(3):200-6.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Rohaizak M, Farndon JR
Use of octreotide and lanreotide in the treatment of symptomatic non-resectable carcinoid tumours. [Journal Article]
ANZ J Surg 2002 Sep; 72(9):635-8.
Abstract | Full Citation | Find Related Articles | | Woltering EA, Mamikunian PM, Zietz S, et al.
Effect of octreotide LAR dose and weight on octreotide blood levels in patients with neuroendocrine tumors. [Journal Article]
Pancreas 2005 Nov; 31(4):392-400.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Dogliotti L, Tampellini M, Stivanello M, et al.
The clinical management of neuroendocrine tumors with long-acting repeatable (LAR) octreotide: comparison with standard subcutaneous octreotide therapy. [Journal Article, Review]
Ann Oncol 2001.:S105-9.
Abstract | Full Citation | Find Related Articles | | Trendle MC, Moertel CG, Kvols LK
Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors. [Journal Article]
Cancer 1997 Feb 15; 79(4):830-4.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |   |
|
| | Enter
www.unboundmedicine.com/medline
in your iPhone browser
or View our
Unbound MEDLINE
iPhone demo
Advertise on this site.
|
